Con­stel­la­tion joins the mega-round club with $100M raise and plans to pur­sue can­cer stud­ies

Af­ter keep­ing a fair­ly low pro­file for the past few years, Con­stel­la­tion Phar­ma­ceu­ti­cals is step­ping in­to the spot­light this morn­ing, join­ing the megaround club in biotech with a broad­ened syn­di­cate of crossover in­vestors that fits the pro­file for com­pa­nies groom­ing them­selves for an IPO.

Adding in a $48 mil­lion round the com­pa­ny brought in at the end of 2016 — but didn’t spot­light — along with a $100 mil­lion round to­day, CEO Ji­gar Raythatha tells me that the com­pa­ny has now raised a to­tal of $280 mil­lion since launch­ing 10 years ago. And the sto­ry the com­pa­ny is telling now cen­ters con­sid­er­ably on a pair of ear­ly-stage can­cer stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER